Response to a monovalent 2009 influenza A (H1N1) vaccine.

Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC Infect Dis (2010) 2.13

Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr (2010) 2.06

Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One (2011) 1.94

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis (2012) 1.80

The shifting demographic landscape of pandemic influenza. PLoS One (2010) 1.66

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52

Concern Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine. PLoS One (2010) 1.51

Serological response in RT-PCR confirmed H1N1-2009 influenza a by hemagglutination inhibition and virus neutralization assays: an observational study. PLoS One (2010) 1.48

Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis (2010) 1.44

Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol (2011) 1.37

Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS One (2011) 1.36

Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol (2010) 1.36

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine (2012) 1.36

Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One (2011) 1.33

Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol (2011) 1.33

How I treat influenza in patients with hematologic malignancies. Blood (2009) 1.32

Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis (2011) 1.28

Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol (2011) 1.26

Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis (2011) 1.21

Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. J R Soc Interface (2011) 1.20

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis (2011) 1.18

Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS One (2010) 1.18

Impact of amino acid mutations in PB2, PB1-F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses. J Virol (2011) 1.17

Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci U S A (2011) 1.17

Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol (2011) 1.17

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One (2011) 1.15

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One (2010) 1.15

CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis (2012) 1.15

Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis (2010) 1.14

The first influenza pandemic of the new millennium. Influenza Other Respir Viruses (2011) 1.14

Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol (2011) 1.14

B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13

Optimal pandemic influenza vaccine allocation strategies for the Canadian population. PLoS One (2010) 1.13

Likely correlation between sources of information and acceptability of A/H1N1 swine-origin influenza virus vaccine in Marseille, France. PLoS One (2010) 1.12

Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol (2011) 1.12

Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol (2011) 1.11

The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biol Sex Differ (2010) 1.10

Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine (2012) 1.09

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica (2010) 1.08

Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One (2011) 1.07

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine (2011) 1.04

Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04

Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One (2011) 1.03

Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol (2011) 1.02

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis (2012) 1.00

Modeling vaccination campaigns and the Fall/Winter 2009 activity of the new A(H1N1) influenza in the Northern Hemisphere. Emerg Health Threats J (2009) 0.98

Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferrets. Clin Vaccine Immunol (2010) 0.98

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis (2012) 0.98

Pandemic (H1N1) 2009 risk for frontline health care workers. Emerg Infect Dis (2011) 0.97

Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One (2012) 0.97

Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study. BMC Infect Dis (2011) 0.95

Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010. PLoS One (2011) 0.95

Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood (2010) 0.93

Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant (2010) 0.92

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol (2010) 0.90

An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol (2010) 0.90

Guidelines on management of human infection with the novel virus influenza A (H1N1)--a report from the Hospital das Clínicas of the University of São Paulo. Clinics (Sao Paulo) (2009) 0.90

Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist (2012) 0.90

Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. Br J Clin Pharmacol (2012) 0.89

The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One (2013) 0.88

Differences in pandemic influenza vaccination policies for pregnant women in Europe. BMC Public Health (2011) 0.88

H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Hum Vaccin Immunother (2015) 0.88

Factors associated with parental acceptance and refusal of pandemic influenza A/H1N1 vaccine in Turkey. Eur J Pediatr (2011) 0.88

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees. BMC Infect Dis (2013) 0.87

Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol (2011) 0.87

Persistence of immunogenicity of a monovalent influenza virus A/H1N1 2009 vaccine in healthy volunteers. Clin Vaccine Immunol (2012) 0.87

A perspective on multiple waves of influenza pandemics. PLoS One (2013) 0.86

Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies. Hum Vaccin Immunother (2014) 0.86

Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol (2011) 0.85

Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore. Emerg Infect Dis (2013) 0.85

Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine. PLoS One (2011) 0.84

Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand. Hum Vaccin Immunother (2012) 0.84

The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One (2015) 0.84

Pandemic influenza vaccines - the challenges. Viruses (2009) 0.84

The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection. J Virol (2012) 0.83

H1N1 infection in emergency surgery: A cautionary tale. Int J Surg Case Rep (2010) 0.83

Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol (2011) 0.83

Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis. BMC Infect Dis (2013) 0.83

Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks. Can J Infect Dis Med Microbiol (2010) 0.83

Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure. Sci Rep (2013) 0.82

Polyvalent AIDS vaccines. Curr HIV Res (2010) 0.82

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth. J Pediatric Infect Dis Soc (2013) 0.82

Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus. J Clin Immunol (2011) 0.81

Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. J Infect Dis (2014) 0.81

The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study. Results Immunol (2012) 0.81

The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months. Trans Am Clin Climatol Assoc (2010) 0.81

Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus. Virol J (2011) 0.81

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis (2012) 0.80

Optimal pandemic influenza vaccine allocation strategies for the canadian population. PLoS Curr (2010) 0.80

Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans. PLoS One (2016) 0.79

Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int (2011) 0.79

A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness. BMC Infect Dis (2014) 0.79

Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A. Virol J (2011) 0.79

The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza. Front Immunol (2016) 0.79

Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus: with special reference to age, body mass index, and HbA1c. Hum Vaccin Immunother (2014) 0.79

Acute transverse myelitis following vaccination against H1N1 influenza: a case report. Int J Clin Exp Pathol (2011) 0.79

Risk factors for acute respiratory infection in the Australian community. PLoS One (2014) 0.79

Immunogenicity and Clinical Efficacy of Influenza Vaccination in Pregnancy. Front Immunol (2015) 0.79

Enhanced viral replication and modulated innate immune responses in infant airway epithelium following H1N1 infection. J Virol (2014) 0.78

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA (2009) 3.32

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine (2008) 1.52

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines (2007) 1.20

A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis (2010) 1.18

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord (2006) 1.11

Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem (2003) 1.07

Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses (2009) 0.92

Mis-expression of the BK K(+) channel disrupts suprachiasmatic nucleus circuit rhythmicity and alters clock-controlled behavior. Am J Physiol Cell Physiol (2012) 0.90

A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr (2009) 0.88

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine (2008) 0.88

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol (2006) 0.87

A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry (2006) 0.85

ISCOMATRIX() vaccines: Safety in human clinical studies. Hum Vaccin (2010) 0.82

Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza Other Respir Viruses (2013) 0.81

A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin Cancer Res (2003) 0.81

Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol (2014) 0.81